Like prior population-based studies, we also found that decreases in breast cancer incidence were only observed for ER-positive cancers [2-4]; however, we did not have a sufficient number of cases to examine trends of ER-defined breast cancers according to HT use, nor could we examine duration of HT use. Here, ESR1 is linked to cancer.